上一張
下一張
The Phase I Clinical Trial Results for Intracranial Implant - Cerebraca® Wafer (an investigational New Drug by Everfront Biotech Inc.) in Recurrent High-Grade Brain Cancer, by Prof. Shinn-Zong Lin in ACNS
Summary
- Cerebraca® Wafer, an investigational new drug developed by Everfront Biotech Inc, has shown excellent safety and efficacy in its Phase I clinical trial for the treatment of recurrent malignant brain tumors.
- The trial involved 12 patients, and those who received the highest dose had an average survival time of more than 19 months.
- Cerebraca® Wafer is designed to clear residual malignant brain tumor cells after surgery and reduce chemoresistance with the help of TMZ.
- The current standard treatments for recurrent malignant brain tumors have limited effectiveness, and there is an urgent need for new therapies.
Latest News
2022/6/9
Everfront Biotech’s Investigational product, Cerebraca® Wafer, has achieved significant progress in Phase I clinical trials for the treatment of malignant brain tumors, and has been invited to speak at the Asian Congress of Neurological Surgeons (ACNS).
2022/4/29
Everfront Biotech’s Cerebraca® Wafer has Completed the Phase I – Safety Evaluation for the Treatment of Glioblastoma Multiforme, and has Initiated the Phase IIa – Efficacy Evaluation
